Report of aids-related lymphoma in South Korea

Jin Soo Kim, Seok Jin Kim, Jinseok Kim, Eun Sun Kim, Ho Jin Shin, Joo Seop Chung, Yoo Hong Min, Moon Hee Lee, Young Jin Choi, Soo Mee Bang, Jung A. Kim, Goon Jae Cho, Hyun Sook Chi, Seong Soo Jang, Chan Jeoung Park, Cheolwon Suh, Chong Won Park, Chul Soo Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea. The aim of this study is to identify the clinical features of ARL in South Korea. Methods: From 1998 through 2006, we retrospectively analysed a total of 23 cases of ARL from seven institutions. Results: The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS. ARL developed at their median age of 41 (range, 24-72). The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included. Ten of 23 (43.5%) was receiving highly active anti-retroviral therapy (HAART) before the diagnosis of ARL. Fifteen of twenty-three patients were given combination chemotherapy with/without radiation, four were given radiation alone, and four did not receive any treatment against medical advice. Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes. The response to treatment included CR in eight (44.4%), PR in four (22.2%) and PD in three (16.7%). The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2%) responded. Estimated median survival time was 43.9 months. Conclusions: Although the population of patients is small, this is the first clinical data analyses of Korean ARL patients. As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.

Original languageEnglish
Pages (from-to)134-139
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume38
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1

Fingerprint

AIDS-Related Lymphoma
Republic of Korea
Lymphoma
Acquired Immunodeficiency Syndrome
Radiation
Therapeutics
T-Cell Lymphoma
B-Cell Lymphoma
CD4 Lymphocyte Count
Combination Drug Therapy
Viral Load
Natural Killer Cells
HIV
T-Lymphocytes
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Kim, J. S., Kim, S. J., Kim, J., Kim, E. S., Shin, H. J., Chung, J. S., ... Kim, C. S. (2008). Report of aids-related lymphoma in South Korea. Japanese Journal of Clinical Oncology, 38(2), 134-139. https://doi.org/10.1093/jjco/hym168
Kim, Jin Soo ; Kim, Seok Jin ; Kim, Jinseok ; Kim, Eun Sun ; Shin, Ho Jin ; Chung, Joo Seop ; Min, Yoo Hong ; Lee, Moon Hee ; Choi, Young Jin ; Bang, Soo Mee ; Kim, Jung A. ; Cho, Goon Jae ; Chi, Hyun Sook ; Jang, Seong Soo ; Park, Chan Jeoung ; Suh, Cheolwon ; Park, Chong Won ; Kim, Chul Soo. / Report of aids-related lymphoma in South Korea. In: Japanese Journal of Clinical Oncology. 2008 ; Vol. 38, No. 2. pp. 134-139.
@article{ecfaedad46404dd28a227fe2bb0c1d21,
title = "Report of aids-related lymphoma in South Korea",
abstract = "Background: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea. The aim of this study is to identify the clinical features of ARL in South Korea. Methods: From 1998 through 2006, we retrospectively analysed a total of 23 cases of ARL from seven institutions. Results: The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS. ARL developed at their median age of 41 (range, 24-72). The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included. Ten of 23 (43.5{\%}) was receiving highly active anti-retroviral therapy (HAART) before the diagnosis of ARL. Fifteen of twenty-three patients were given combination chemotherapy with/without radiation, four were given radiation alone, and four did not receive any treatment against medical advice. Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes. The response to treatment included CR in eight (44.4{\%}), PR in four (22.2{\%}) and PD in three (16.7{\%}). The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2{\%}) responded. Estimated median survival time was 43.9 months. Conclusions: Although the population of patients is small, this is the first clinical data analyses of Korean ARL patients. As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.",
author = "Kim, {Jin Soo} and Kim, {Seok Jin} and Jinseok Kim and Kim, {Eun Sun} and Shin, {Ho Jin} and Chung, {Joo Seop} and Min, {Yoo Hong} and Lee, {Moon Hee} and Choi, {Young Jin} and Bang, {Soo Mee} and Kim, {Jung A.} and Cho, {Goon Jae} and Chi, {Hyun Sook} and Jang, {Seong Soo} and Park, {Chan Jeoung} and Cheolwon Suh and Park, {Chong Won} and Kim, {Chul Soo}",
year = "2008",
month = "2",
day = "1",
doi = "10.1093/jjco/hym168",
language = "English",
volume = "38",
pages = "134--139",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

Kim, JS, Kim, SJ, Kim, J, Kim, ES, Shin, HJ, Chung, JS, Min, YH, Lee, MH, Choi, YJ, Bang, SM, Kim, JA, Cho, GJ, Chi, HS, Jang, SS, Park, CJ, Suh, C, Park, CW & Kim, CS 2008, 'Report of aids-related lymphoma in South Korea', Japanese Journal of Clinical Oncology, vol. 38, no. 2, pp. 134-139. https://doi.org/10.1093/jjco/hym168

Report of aids-related lymphoma in South Korea. / Kim, Jin Soo; Kim, Seok Jin; Kim, Jinseok; Kim, Eun Sun; Shin, Ho Jin; Chung, Joo Seop; Min, Yoo Hong; Lee, Moon Hee; Choi, Young Jin; Bang, Soo Mee; Kim, Jung A.; Cho, Goon Jae; Chi, Hyun Sook; Jang, Seong Soo; Park, Chan Jeoung; Suh, Cheolwon; Park, Chong Won; Kim, Chul Soo.

In: Japanese Journal of Clinical Oncology, Vol. 38, No. 2, 01.02.2008, p. 134-139.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Report of aids-related lymphoma in South Korea

AU - Kim, Jin Soo

AU - Kim, Seok Jin

AU - Kim, Jinseok

AU - Kim, Eun Sun

AU - Shin, Ho Jin

AU - Chung, Joo Seop

AU - Min, Yoo Hong

AU - Lee, Moon Hee

AU - Choi, Young Jin

AU - Bang, Soo Mee

AU - Kim, Jung A.

AU - Cho, Goon Jae

AU - Chi, Hyun Sook

AU - Jang, Seong Soo

AU - Park, Chan Jeoung

AU - Suh, Cheolwon

AU - Park, Chong Won

AU - Kim, Chul Soo

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Background: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea. The aim of this study is to identify the clinical features of ARL in South Korea. Methods: From 1998 through 2006, we retrospectively analysed a total of 23 cases of ARL from seven institutions. Results: The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS. ARL developed at their median age of 41 (range, 24-72). The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included. Ten of 23 (43.5%) was receiving highly active anti-retroviral therapy (HAART) before the diagnosis of ARL. Fifteen of twenty-three patients were given combination chemotherapy with/without radiation, four were given radiation alone, and four did not receive any treatment against medical advice. Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes. The response to treatment included CR in eight (44.4%), PR in four (22.2%) and PD in three (16.7%). The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2%) responded. Estimated median survival time was 43.9 months. Conclusions: Although the population of patients is small, this is the first clinical data analyses of Korean ARL patients. As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.

AB - Background: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea. The aim of this study is to identify the clinical features of ARL in South Korea. Methods: From 1998 through 2006, we retrospectively analysed a total of 23 cases of ARL from seven institutions. Results: The patients consisted of 20 males and 3 females at a median age of 40 (range, 20-72) on diagnosis of AIDS. ARL developed at their median age of 41 (range, 24-72). The histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/T cell lymphoma were also included. Ten of 23 (43.5%) was receiving highly active anti-retroviral therapy (HAART) before the diagnosis of ARL. Fifteen of twenty-three patients were given combination chemotherapy with/without radiation, four were given radiation alone, and four did not receive any treatment against medical advice. Of 20 patients followed-up, nine were alive in remission, two alive in disease, one died of treatment related complication, four died of progressive lymphoma, four died of AIDS related causes. The response to treatment included CR in eight (44.4%), PR in four (22.2%) and PD in three (16.7%). The response to HARRT was evaluable in 13 patients based on CD4+ cell count and HIV viral load, among which nine (69.2%) responded. Estimated median survival time was 43.9 months. Conclusions: Although the population of patients is small, this is the first clinical data analyses of Korean ARL patients. As a substantial portion of the patients remains alive disease free, the impact of HAART on the clinical course of ARL needs further follow-up and evaluation.

UR - http://www.scopus.com/inward/record.url?scp=40349105712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349105712&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym168

DO - 10.1093/jjco/hym168

M3 - Article

VL - 38

SP - 134

EP - 139

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -